Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:4553
Structure:
Synonyms:
123653-11-2
AC1L1IF7
AC1Q20LP
AR-1K3665
Bio2_000472
Bio2_000952
BRD-K53364951-001-02-6
BSPBio_001264
C080955
C13H18N2O5S
CCRIS 8523
CHEBI:101699
CHEMBL7162
HMS1362P05
HMS1792P05
HMS1990P05
I14-10018
IDI1_002227
IN1319
KBio2_000604
KBio2_003172
KBio2_005740
KBio3_001067
KBio3_001068
KBioGR_000604
KBioSS_000604
LS-90104
Methanesulfonamide, N-(2-(cyclohexyloxy)-4-nitrophenyl)-
N-(2-Cyclohexyloxy-4-nitrophenyl)methanesulfonamide
N-[2-(Cyclohexyloxy)-4-nitrophenyl]methanesulfonamide
N194_SIGMA
NCGC00024892-01
NCGC00024892-02
NCGC00024892-03
nchembio.147-comp10
NS 398
NS-398
NS398
NS4
Tocris-0942
ZINC03791739

Target

show target details
Uniprot ID:Q6LEN2_HUMAN
Synonyms:
Prostacyclin synthase
EC-Numbers:5.3.99.4
Organism:Homo sapiens
Human
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

10199864
COX-2 and cytosolic PLA2 mediate IL-1beta-induced cAMP production in human vascular smooth muscle cells.. D Beasley (1999) The American journal of physiology display abstract
Interleukin (IL)-1 is a potent vasodilator that causes prolonged induction of prostacyclin (PGI2) and cAMP synthesis in human vascular smooth muscle cells (HVSMC). The present study investigated IL-1 induction of PG synthetic enzymes in HVSMC and tested their respective roles in PGI2 and cAMP production. Cyclooxygenase (COX)-1 mRNA was not detectable in either control or IL-1-treated HVSMC, as assessed by RT-PCR. In contrast, COX-2 mRNA was detectable in control HVSMC, increased markedly (16-fold) after 1 h of IL-1 exposure, and increased further (52-fold) after 24 h. COX-2 protein levels, assessed by Western analysis, were increased concomitantly. HVSMC contained mRNA encoding both the secreted and cytosolic forms of phospholipase A2 (sPLA2 and cPLA2, respectively). IL-1 stimulation did not affect sPLA2 mRNA levels, but cPLA2 mRNA levels increased at 8 h, after the initial induction of PG synthesis. HVSMC constitutively expressed PGI2 synthase mRNA, and its levels were not affected by IL-1. A selective COX-2 inhibitor, NS-398, reversed IL-1-induced PGI2 and cAMP production, supporting a role of COX-2 in mediating increased PG synthesis. IL-1-induced cAMP was also reversed by a selective cPLA2 inhibitor, AACOCF3, but not by thioetheramide phosphorylcholine, which inhibits sPLA2 preferentially over cPLA2, supporting a requirement for cPLA2-derived arachidonic acid in IL-1-induced PG synthesis. The delayed induction of cPLA2 mRNA was also attenuated by NS-398, suggesting that it was secondary to the initial COX-2-induced PG synthesis. Together, the results support the hypothesis that IL-1 induces intracellular PG synthesis in HVSMC via rapid upregulation of COX-2, which utilizes cPLA2-derived arachidonic acid to generate PG metabolites that regulate adenylate cyclase.